AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently amended) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6 ppm to 0.568% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O_5 and having a sedimentation velocity of 0.8 cm/s or lower.
- 2. (Currently amended) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 120 ppm to 0.568% by weight of zinc, 33-57% by weight of P₂O₅, 10-65% by weight of CaO and 0-28% by weight of H₂O, and having a sedimentation velocity of 0.8 cm/s or lower.
- 3. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said microparticle of zinc-containing calcium phosphate comprises one or more compounds selected from zinc-containing hydroxyapatite, zinc-containing poorly-crystallized apatite, zinc-containing α -tricalcium phosphate, zinc-containing β -tricalcium phosphate, zinc-containing calcium hydrogenphosphate, zinc-containing amorphous calcium phosphate and $CaZn_2(PO_4)_2$ nH_2O ($0 \le n \le 2$).
- 4. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, further comprising at least one osteogenic compound

selected from vitamin D, α -calcidol, estrogen-related preparations, calcitonin, bisphosphonate and calcium containing preparations.

- 5. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said liquid comprises one or more water-miscible solvents selected from physiological saline solution, an aqueous solution of 2.5% by weight or less of sodium chloride, Ringer's solution, purified water, distilled water for injection, distilled water, physiological salt solution, propylene glycol, and ethanol.
- 6. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said liquid comprises one or more water-immiscible solvents selected from triglyceride, safflower oil, soybean oil, sesame oil, rapeseed oil, peanut oil, and polyethylene glycols (Macrogol).
- 7. (Previously presented) The suspension or particle-solvent mixture system according to claim 1 or 2, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.
- 8. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency and as an osteogenetic agent.
- 9. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, further comprising at least one osteogenic compound

selected from vitamin D, α -calcidol, estrogen-related preparations, calcitonin, bisphosphonate and calcium containing preparations.

- 10. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, wherein said liquid comprises one or more water-miscible solvents selected from physiological saline solution, an aqueous solution of 2.5% by weight or less of sodium chloride, Ringer's solution, purified water, distilled water for injection, distilled water, physiological salt solution, propylene glycol, and ethanol.
- 11. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said liquid comprises one or more water-miscible solvents selected from physiological saline solution, an aqueous solution of 2.5% by weight or less of sodium chloride, Ringer's solution, purified water, distilled water for injection, distilled water, physiological salt solution, propylene glycol, and ethanol.
- 12. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, wherein said liquid comprises one or more water-immiscible solvents selected from triglyceride, safflower oil, soybean oil, sesame oil, rapeseed oil, peanut oil, and polyethylene glycols (Macrogol).
- 13. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said liquid comprises one or more water-immiscible solvents selected from triglyceride, safflower oil, soybean oil, sesame oil, rapeseed oil, peanut oil, and polyethylene glycols (Macrogol).

- 14. (Previously presented) The suspension or particle-solvent mixture system according to claim 3, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.
- 15. (Previously presented) The suspension or particle-solvent mixture system according to claim 4, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.
- 16. (Previously presented) The suspension or particle-solvent mixture system according to claim 5, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.
- 17. (Previously presented) The suspension or particle-solvent mixture system according to claim 6, wherein said suspension or particle-solvent mixture system is used as a therapeutic agent for treating zinc deficiency.
- 18. (New) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6 ppm to 13% by weight of zinc, 33-57% by weight of P₂O₅, 10-65% by weight of CaO and 0-28% by weight of H₂O, wherein said microparticle comprises zinc-containing calcium phosphate glass.
- 19. (New) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6ppm to 13% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , and having a sedimentation velocity of 0.8 cm/s or lower, wherein the zinc-containing calcium phosphate does not comprise zinc-containing β -tricalcium phosphate or $CaZn_2(PO_4)_2$.

20. (New) A suspension or particle-solvent mixture system which comprises a liquid comprising a microparticle of zinc-containing calcium phosphate comprising from 0.6ppm to 13% by weight of zinc, 33-57% by weight of P_2O_5 , 10-65% by weight of CaO and 0-28% by weight of H_2O , and having a sedimentation velocity of 0.8 cm/s or lower, wherein said microparticle of zinc-containing calcium phosphate comprises one or more compounds selected from zinc-containing calcium hydrogenphosphate, zinc-containing amorphous calcium phosphate, zinc-containing α -tricalcium phosphate, zinc-containing poorly-crystallized apatite, $CaZn_2(PO_4)_2 \cdot H_2O$, and $CaZn_2(PO_4)_2 \cdot 2H_2O$.